293 related articles for article (PubMed ID: 34669521)
1. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
Choe H; Ferrara JLM
Expert Opin Ther Targets; 2021 Sep; 25(9):761-771. PubMed ID: 34669521
[TBL] [Abstract][Full Text] [Related]
2. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.
Kasikis S; Etra A; Levine JE
BioDrugs; 2021 Jan; 35(1):19-33. PubMed ID: 33201499
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease.
Renteria AS; Levine JE; Ferrara JLM
Expert Opin Orphan Drugs; 2016; 4(5):469-484. PubMed ID: 30057862
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application.
Srinagesh HK; Ferrara JLM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101111. PubMed ID: 31779977
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
9. Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease.
Zeng K; Brewster R; Kang JB; Tkachenko E; Brooks E; Bhatt AS; Fodor AA; Andermann TM
Transplant Cell Ther; 2024 Feb; 30(2):237.e1-237.e9. PubMed ID: 37944820
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
11. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
[TBL] [Abstract][Full Text] [Related]
12. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.
Gergoudis SC; DeFilipp Z; Özbek U; Sandhu KS; Etra AM; Choe HK; Kitko CL; Ayuk F; Aziz M; Baez J; Ben-David K; Bunworasate U; Gandhi I; Hexner EO; Hogan WJ; Holler E; Kasikis S; Kowalyk SM; Lin JY; Merli P; Morales G; Nakamura R; Reshef R; Rösler W; Srinagesh H; Young R; Chen YB; Ferrara JLM; Levine JE
Blood Adv; 2020 Dec; 4(24):6098-6105. PubMed ID: 33351103
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.
Bhattarai A; Shah S; Yadav R; Dhakal G; Neupane R; Paudel S; Bhandari P; Abu Serhan H; Sah R; Sah S; Barboza JJ
Hematology; 2024 Dec; 29(1):2293497. PubMed ID: 38112182
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
18. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
19. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
